| 5 0.51 (11.36%) | 11-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.42 | 1-year : | 5.17 |
| Resists | First : | 3.78 | Second : | 4.42 |
| Pivot price | 3.47  |
|||
| Supports | First : | 3.17 | Second : | 2.79 |
| MAs | MA(5) : | 3.63 |
MA(20) : | 3.37 |
| MA(100) : | 2.95 |
MA(250) : | 2.68 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 79 |
D(3) : | 85 |
| RSI | RSI(14): 55.1 |
|||
| 52-week | High : | 5.09 | Low : | 1.63 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VACC ] has closed below upper band by 43.5%. Bollinger Bands are 40% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.76 - 3.77 | 3.77 - 3.79 |
| Low: | 3.48 - 3.5 | 3.5 - 3.51 |
| Close: | 3.49 - 3.52 | 3.52 - 3.55 |
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Mon, 18 Sep 2023
Oxford and Liverpool scientists launch new vaccine trial for Middle East Respiratory Syndrome (MERS) - University of Oxford
Mon, 30 Jan 2023
Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer - GlobeNewswire
Mon, 17 Jan 2022
Avidea Merger with Vaccitech Provides New Opportunities for SNAPvax Platform - BioBuzz
Fri, 30 Apr 2021
Vaccitech, startup behind Oxford COVID-19 vaccine tech, falls 20% in Nasdaq debut - Reuters
Mon, 26 Apr 2021
Biotech behind AstraZeneca vaccine aims to raise $117m at IPO - Financial Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 2.83e+007 (%) |
| Held by Institutions | 3.4 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.291e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 717.9 % |
| Return on Equity (ttm) | -15.2 % |
| Qtrly Rev. Growth | 1.342e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.34 |
| EBITDA (p.s.) | -1.64 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -20 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 10.11 |
| Price to Cash Flow | -0.25 |
| Dividend | 0 |
| Forward Dividend | 159220 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|